Low Intensity Ultrasound Therapy for Upper Back Pain Relief

The study will have approximately 33 subjects randomly assigned into a user group (active ultrasound device) of 25 participants or a control group (inactive ultrasound device) of 8 participants with an equal number of males and females in each group. The research coordinator will be blinded to the assignment of devices to each group.

The daily pain scores reported by patients who receive active devices will be compared to those who receive placebo devices.

Background:

Approximately 50 to 80 million people in the United States suffer from some form of chronic pain. Back pain is the most common neurological disorder in the United States after headaches and costs consumers nearly $50 billion annually. Pharmaceuticals currently dominate the treatment options despite a myriad of public health problems including cost, untoward side effects, and addiction to widely available opioid analgesics. Non-pharmaceutical treatments, such as the one under test, provide a safer and potentially lower cost alternative to traditional analgesic use.

Inclusion criteria

• Between the ages of 18 and 65 years.
• Has acute trapezius muscle pain that has been assessed by a health care practitioner.
• Has a NRS pain severity score of 3.0 or higher in the trapezius muscle 3-4 times over the past week prior to enrolling in the trial.
• Subjects must be willing and able to self-administer treatment daily within their place of residence or during normal daily activity, excluding bathing, showering, or other water activities which may result in submersion of the device under test.
• Not taken any prescription pain medications or muscle relaxers in the 5 days prior to the study and agree not to take any during the study and to maintain any dosage of NSAIDs (nonsteroidal antiinflammatory drug) or non-prescription pain medications constant during the study
• Has access to a mobile phone or camera and the help of another individual to take a picture of the upper back area immediately after use of the device

Exclusion criteria

• Subjects with known neuropathy will be excluded from the study
• Women who are pregnant may not participate.
• Prisoners
• Smokers
• Subjects with Type I or Type II Diabetes
• Subjects who have had surgery in the target area within the last 6 months will be excluded from the study.
• Subjects who are non-ambulatory (i.e. who cannot walk) will be excluded from the study.
• Subjects who refuse to agree to not increase current use or initiate new use of pain medication during the course of the trial unless medically necessary to ensure patient safety.
• Subjects who refuse to agree to not use any cream, gel, or topical solution during the administration of treatment other than the approved ultrasound gel provided to the subject at the initiation of the study.
• Subjects who refuse to discontinue massage therapy or spinal manipulation during the duration of this study.
• Subjects who have had massage therapy within 1 day of beginning the protocol
• Subjects who refuse to discontinue all other interventional treatment modalities (i.e. transcutaneous electrical nerve stimulation (TENS), ultrasound)
• Subjects who had a local corticosteroid or PRP (platelet-rich plasma) injection within the past 3 months.
• Subjects who have a clinically significant or unstable medical or psychological conditions that would compromise participation in the study.
• Subjects who have participated in another clinical trial for an investigational drug and/or agent within 30 days prior to screening.
• Subjects involved in any injury-related litigation in the target area.
• Subjects with abnormal neurological history, lumbar radicular symptoms, spinal stenosis, foot drop, herniated nucleus pulposus (gel-like substance within a spinal disc), or other structural defects.
• Subjects with back pain related to major trauma in the last 6 months
• Subjects with open sores or wounds in the treatment area that would prevent use of the device